Amgen shot down in attempt to bar Neupogen biosimilar in U.S.

• The U.S. Court of Appeals for the Federal Circuit rejects Amgen's (AMGN -0.5%) attempt to block Novartis' (NVS -1.7%) Sandoz unit from launching Zarxio (filgrastim - sndz), a biosimilar to Neupogen (filgrastim), in the U.S. The current injunction will remain in place until September 2.
• A district court rebuffed Amgen in March. The FDA approved Zarxio on March 6.
• Previously: Court rejects Amgen's bid to block Neupogen biosimilar (March 20)
• Previously: FDA clears first biosimilar (March 6)